開發新穎藥物用以治療
惡性神經膠母細胞瘤的新策略

主要領域 癌症治療

- **產品/技術簡介**
  - 『**人工智能**』藥物研發模型，設計高潛力之小分子藥物。
  - 『**智慧合成**』藥物合成策略，進行高效率之藥物合成。
- **應用**
  - 從臨床資料庫中鑑別出與藥理及致病等相關之關鍵蛋白質標靶，目標針對這些標靶研發新穎藥物用以治療惡性神經膠母細胞瘤。
- **優勢**
  - 目前之先導藥物在數種動物模型以口服方式給藥皆展現良好效果。
  - 具有創新藥物研發專業，及兩項技術轉移與創立兩間新創公司之豐富經驗。

Sub-project 1
AI Platform
許凱程

Sub-project 2
**Smart Synthesis**
謝興邦

Novel Strategy for Discovery of Inhibitors against GBM

Sub-project 3
Character Validation
潘秀玲

Novel Strategy for Discovery of Inhibitors against Glioblastoma

Research Area | **Cancer Treatment**

- ## Technical statement
  - An artificial intelligence (AI) platform for designing inhibitors.
  - A smart synthesis approach to efficiently and precisely synthesize a focused library.

- ## Applications
  - We have identified critical targets with important pharmacological and pathological roles in GBM tumor development by analyzing clinical data.

- ## Advantages
  - Current potential lead compounds showed potent *in vivo* efficacy by oral administration in several animal models.
  - We have expertise with developing novel therapeutic drugs, and experience with twice technology transfer and launching two startup companies.

Sub-project 1
AI Platform
許凱程

Sub-project 2
Smart Synthesis
謝興邦

Novel Strategy for Discovery of Inhibitors against GBM

Sub-project 3
Character Validation
潘秀玲

Dr. 許凱程
Kai-Cheng Hsu

Dr. 謝興邦
Hsing-Pang Hsieh

Dr. 潘秀玲
Shiow-Lin Pan

Dr. 李昆鴻
Dr. 李慕珺
Dr. 杜皇儒
郭奕辰
宋姿瑩

- **Contact person: Dr. 謝興邦**
- **TEL: +886-2-7750-5500**
- **Email: alexhsieh@gate.sinica.edu.tw**